159 related articles for article (PubMed ID: 10589943)
1. Differences in gastric motor activity in renal transplant recipients treated with FK-506 versus cyclosporine.
Maes BD; Vanwalleghem J; Kuypers D; Ghoos Y; Rutgeerts PJ; Vanrenterghem YF
Transplantation; 1999 Nov; 68(10):1482-5. PubMed ID: 10589943
[TBL] [Abstract][Full Text] [Related]
2. Gastric emptying time in renal transplant recipients treated with cyclosporine.
Ozkaya O; Derici U; Buyan N; Dalgic A; Dalgic B; Cingi E; Kitapci M; Sindel S; Hasanoglu E
Transplant Proc; 2003 Dec; 35(8):2927-30. PubMed ID: 14697940
[TBL] [Abstract][Full Text] [Related]
3. Influence of SDZ RAD vs. MMF on gastric emptying in renal transplant recipients.
Maes BD; Evenepoel P; Kuypers D; Geypens B; Ghoos Y; Vanrenterghem Y
Clin Transplant; 2003 Jun; 17(3):171-6. PubMed ID: 12780664
[TBL] [Abstract][Full Text] [Related]
4. Conversion of renal transplant immunosuppression from tacrolimus (FK 506) to cyclosporine: a single center experience.
Ichikura H; Tanabe K; Tokumoto T; Shimuzu T; Ishikawa N; Harano M; Inui M; Manu M; Ito S; Shimmura H; Okuda H; Yagisawa T; Fuchinoue S; Toma H
Transplant Proc; 2000 Nov; 32(7):1733-5. PubMed ID: 11119911
[No Abstract] [Full Text] [Related]
5. Lipoprotein patterns in renal transplant patients: a comparison between FK 506 and cyclosporine A patients.
Claesson K; Mayer AD; Squifflet JP; Grabensee B; Eigler FW; Behrend M; Vanrenterghem Y; van Hooff J; Morales JM; Johnson RW; Buchholz B; Land W; Forsythe JL; Neumayer HH; Ericzon BG; Mühlbacher F
Transplant Proc; 1998 Jun; 30(4):1292-4. PubMed ID: 9636524
[No Abstract] [Full Text] [Related]
6. Clinical study of FK 506 in renal transplant recipients.
Youhua Z; Zhinlian M; Liming W
Transplant Proc; 2000 Nov; 32(7):1704. PubMed ID: 11119900
[No Abstract] [Full Text] [Related]
7. Tacrolimus (FK 506) in kidney transplantation: three-year survival results of the US multicenter, randomized, comparative trial. FK 506 Kidney Transplant Study Group.
Jensik SC
Transplant Proc; 1998 Jun; 30(4):1216-8. PubMed ID: 9636494
[No Abstract] [Full Text] [Related]
8. Low-density lipoprotein oxidizability and the alteration of its fatty acid content in renal transplant recipients treated with cyclosporine/tacrolimus.
Bakar F; Keven K; Dogru B; Aktan F; Erturk S; Tuzuner A; Erbay B; Nebioglu S
Transplant Proc; 2009 Jun; 41(5):1630-3. PubMed ID: 19545695
[TBL] [Abstract][Full Text] [Related]
9. Randomized trial of tacrolimus versus cyclosporine in steroid withdrawal in living donor renal transplant recipients.
Kim SJ; Lee KW; Lee DS; Lee HH; Lee SK; Kim B; Huh WS; Oh HY; Joh JW
Transplant Proc; 2004 Sep; 36(7):2098-100. PubMed ID: 15518759
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the temporal profile of calcineurin inhibition by cyclosporine and tacrolimus in renal transplant patients.
Koefoed-Nielsen PB; Karamperis N; Jørgensen KA
Transplant Proc; 2005 May; 37(4):1736-8. PubMed ID: 15919449
[TBL] [Abstract][Full Text] [Related]
11. Immunosuppression switch in pediatric heart transplant recipients: cyclosporine to FK 506.
Swenson JM; Fricker FJ; Armitage JM
J Am Coll Cardiol; 1995 Apr; 25(5):1183-8. PubMed ID: 7534779
[TBL] [Abstract][Full Text] [Related]
12. Early steroid withdrawal in pediatric renal transplantation at a single center: preliminary report.
Valenzuela M; Delucchi A; Ferrario M; Lillo AM; Guerrero JL; Rodríguez E; Cano F; Cavada G
Transplant Proc; 2008 Nov; 40(9):3237-40. PubMed ID: 19010242
[TBL] [Abstract][Full Text] [Related]
13. High incidence of severe infections in heart transplant recipients receiving tacrolimus.
Peraira JR; Segovia J; Arroyo R; Ortiz P; Fuertes B; Moñivas V; Burgos R; Alonso-Pulpón L
Transplant Proc; 2003 Aug; 35(5):1999-2000. PubMed ID: 12962875
[TBL] [Abstract][Full Text] [Related]
14. Role of protocol biopsies in the treatment of refractory renal allograft rejection with FK 506.
Woodle ES; Thistlethwaite JR; Haas M; Josephson MA; Newell KA; Bruce DS; Millis JM; Piper JB; Charette JI
Transplant Proc; 1996 Apr; 28(2):998-9. PubMed ID: 8623495
[No Abstract] [Full Text] [Related]
15. Nephrotoxic effects of primary immunosuppression with FK-506 and cyclosporine regimens after liver transplantation.
Porayko MK; Textor SC; Krom RA; Hay JE; Gores GJ; Richards TM; Crotty PH; Beaver SJ; Steers JL; Wiesner RH
Mayo Clin Proc; 1994 Feb; 69(2):105-11. PubMed ID: 7508536
[TBL] [Abstract][Full Text] [Related]
16. Pronounced renal vasoconstriction and systemic hypertension in renal transplant patients treated with cyclosporin A versus FK 506.
Radermacher J; Meiners M; Bramlage C; Kliem V; Behrend M; Schlitt HJ; Pichlmayr R; Koch KM; Brunkhorst R
Transpl Int; 1998; 11(1):3-10. PubMed ID: 9503547
[TBL] [Abstract][Full Text] [Related]
17. Reversal of accelerated renal allograft rejection with FK 506.
Woodle ES; Newell KA; Haas M; Bartosh S; Josephson MA; Millis JM; Bruce DS; Piper JB; Aronson AJ; Thistlethwaite JR
Clin Transplant; 1997 Aug; 11(4):251-4. PubMed ID: 9267710
[TBL] [Abstract][Full Text] [Related]
18. Conversion from cyclosporine to tacrolimus in kidney, kidney/pancreas, and pancreas alone transplant recipients: the Memphis experience.
Alloway RR; Russell WC; Gaber LW; Amiri MH; Vera SR; Gaber AO
Transplant Proc; 1996 Apr; 28(2):995-7. PubMed ID: 8623494
[No Abstract] [Full Text] [Related]
19. Preliminary experience with FK 506 in pediatric renal transplant recipients: a single-center report.
Birk PE; Cook ME; Schmidt WJ; Chavers BM
Transplant Proc; 1996 Apr; 28(2):993-4. PubMed ID: 8623493
[No Abstract] [Full Text] [Related]
20. Immunosuppression in cadaveric renal transplant recipients from non-heart-beating donors in a single center.
Ushigome H; Okamoto M; Kadotani Y; Nakamura K; Akioka K; Ohmori Y; Yoshimura N
Transplant Proc; 2002 Aug; 34(5):1681-2. PubMed ID: 12176533
[No Abstract] [Full Text] [Related]
[Next] [New Search]
